%0 Journal Article %J The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions %D 2002 %T The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. %A Rainey, Petrie M %A Friedland, Gerald H %A Snidow, Jerry W %A McCance-Katz, Elinore F %A Mitchell, Susan M %A Andrews, Laurie %A Lane, Barbara %A Jatlow, Peter %K Adolescent %K Adult %K Anti-HIV Agents %K Drug Combinations %K Female %K HIV Seropositivity %K Humans %K Lamivudine %K Male %K Methadone %K Middle Aged %K Narcotics %K Opioid-Related Disorders %K Zidovudine %N 1 %P 66-74 %V 11 %X Methadone pharmacokinetics were determined in an open-label, within subject study in 16 methadone-maintained, non-HIV-infected subjects prior to and following administration of one lamivudine 150-mg/zidovudine 300-mg combination tablet to determine whether this antiretroviral therapy alters methadone serum concentrations. No significant differences in the mean area under the serum concentration-time curve (AUC(0-24h); 8,753 +/- 4,280 vs. 8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs. 10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected. These results suggest that methadone dose change is not likely to be necessary for patients treated with lamivudine/zidovudine combination pharmacotherapy. %8 2002 Winter